8-K
filed June 3, 2026, 7:30 AM ET
ticker RGNX
CIK 0001590877
other material
confidence high
sentiment negative
materiality 0.35
REGENXBIO shareholders reject executive stock option exchange; approve non-executive program
REGENXBIO Inc.
- At 2026 annual meeting, shareholders voted against executive stock option exchange: 21,021,531 against, 14,097,815 for.
- Shareholders approved non-executive stock option exchange: 26,352,456 for, 8,853,230 against. Company commenced program on June 3.
- Exchange offer runs June 3–July 1, 2026; eligible options must have exercise price ≥ $18.00.
- Directors elected: Jean Bennett, Jerry Karabelas, Daniel Tassé; PwC ratified as auditor; advisory say-on-pay approved.
- Program not expected to significantly change stock compensation expense.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENXBIO Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: Votes For Votes Against Votes Abstaining Broker Non-Votes 42,526,553 244,785 47,545 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENXBIO Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,392,302 2,722,825 149,635 7,554,121
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENXBIO Inc. shareholders approved Election of three Class II directors at the 2026-05-29 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 1 : By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2029 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes Jean Bennett, M.D., Ph.D. 24,025,836 11,238,926 7,554,121 A.N. “Jerry” Karabelas, Ph.D. 27,124,923 8,139,839 7,554,121 Daniel Tassé 32,039,753 3,225,009 7,554,121
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENXBIO Inc. shareholders approved Approval of Stock Option Exchange Program for non-executive employees at the 2026-05-29 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 4 : By the following vote, the stockholders approved, the Stock Option Exchange Program for the Company’s non-executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 26,352,456 8,853,230 59,076 7,554,121
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENXBIO Inc. shareholders rejected Stock Option Exchange Program for executive employees at the 2026-05-29 meeting.
- Outcome
- failed
- Meeting
- 2026-05-29
Exact text from the filing
Proposal 5 : By the following vote, the stockholders did not approve, a Stock Option Exchange Program for the Company’s executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 14,097,815 21,021,531 145,416 7,554,121
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.